195 related articles for article (PubMed ID: 24319183)
1. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Paschka P; Döhner K
Hematology Am Soc Hematol Educ Program; 2013; 2013():209-19. PubMed ID: 24319183
[TBL] [Abstract][Full Text] [Related]
2. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
3. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
[TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
[TBL] [Abstract][Full Text] [Related]
5. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Marcucci G; Caligiuri MA; Bloomfield CD
Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
[TBL] [Abstract][Full Text] [Related]
7. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret H; Preudhomme C; Boissel N
Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
9. Core binding factor acute myeloid leukemia.
Paschka P
Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
12. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Solh M; Yohe S; Weisdorf D; Ustun C
Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
[TBL] [Abstract][Full Text] [Related]
13. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
[TBL] [Abstract][Full Text] [Related]
14. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
Paschka P; Marcucci G; Ruppert AS; Mrózek K; Chen H; Kittles RA; Vukosavljevic T; Perrotti D; Vardiman JW; Carroll AJ; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2006 Aug; 24(24):3904-11. PubMed ID: 16921041
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Ayatollahi H; Shajiei A; Sadeghian MH; Sheikhi M; Yazdandoust E; Ghazanfarpour M; Shams SF; Shakeri S
Hematol Oncol Stem Cell Ther; 2017 Mar; 10(1):1-7. PubMed ID: 27613372
[TBL] [Abstract][Full Text] [Related]
16. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
17. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; von Neuhoff C; Sander A; Schrauder A; Teigler-Schlegel A; Stary J; Corbacioglu S; Reinhardt D
Blood; 2011 Nov; 118(20):5409-15. PubMed ID: 21948298
[TBL] [Abstract][Full Text] [Related]
18. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
[TBL] [Abstract][Full Text] [Related]
19. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
Ustun C; Marcucci G
Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
[TBL] [Abstract][Full Text] [Related]
20. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
